Broderick Brian C Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Broderick Brian C increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 105.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,512 shares of the company’s stock after acquiring an additional 2,832 shares during the quarter. Broderick Brian C’s holdings in Eli Lilly and Company were worth $4,552,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Lion Street Advisors LLC grew its stake in shares of Eli Lilly and Company by 12.3% in the first quarter. Lion Street Advisors LLC now owns 510 shares of the company’s stock worth $421,000 after purchasing an additional 56 shares during the last quarter. Cornerstone Wealth Management LLC raised its position in Eli Lilly and Company by 8.3% during the 1st quarter. Cornerstone Wealth Management LLC now owns 4,142 shares of the company’s stock valued at $3,421,000 after purchasing an additional 319 shares during the last quarter. Bender Robert & Associates lifted its holdings in Eli Lilly and Company by 0.7% in the 1st quarter. Bender Robert & Associates now owns 18,419 shares of the company’s stock worth $15,212,000 after buying an additional 136 shares during the period. Shepherd Financial Partners LLC lifted its holdings in Eli Lilly and Company by 3.8% in the 1st quarter. Shepherd Financial Partners LLC now owns 9,507 shares of the company’s stock worth $7,852,000 after buying an additional 350 shares during the period. Finally, Hemenway Trust Co LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $4,696,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LLY. Cantor Fitzgerald began coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 target price for the company. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. UBS Group decreased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Erste Group Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Finally, Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,011.37.

Eli Lilly and Company Price Performance

LLY stock opened at $791.61 on Wednesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a 50 day moving average price of $777.90 and a 200-day moving average price of $801.70. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The firm has a market capitalization of $750.24 billion, a price-to-earnings ratio of 64.41, a PEG ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm’s quarterly revenue was up 45.2% on a year-over-year basis. During the same period last year, the business earned $2.58 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. Eli Lilly and Company’s payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.